Premium
Is secondary lymphoid‐organ chemokine (SLC/CCL21) much more than a constitutive chemokine?
Author(s) -
Serra H. M.,
BaenaCagnani C. E.,
Eberhard Y.
Publication year - 2004
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2004.00531.x
Subject(s) - ccl21 , chemokine , ccl13 , biology , cxcl13 , immunology , xcl2 , angiogenesis , ccl17 , lymph node stromal cell , c c chemokine receptor type 7 , stromal cell , ccr10 , high endothelial venules , microbiology and biotechnology , lymphatic system , cxcl2 , cxcl10 , chemokine receptor , immune system , cancer research
Chemokines are a superfamily of small cytokines with activities ranging from leukocyte traffick to hematopoiesis, angiogenesis, and tissue organogenesis. Secondary lymphoid‐organ chemokine (SLC/CCL21) was originally reported as a chemokine constitutively expressed by stromal cells and high endothelial venules in secondary lymphoid tissues and endothelium of afferent lymphatics, directing CCR7 + cells. More recently, others and we have demonstrated that SLC/CCL21 is up‐regulated in different skin inflammatory conditions. Thereafter, this molecule is much more than a constitutive chemokine, which could play a role in effector and regulatory immune functions.